JP2004525602A5 - - Google Patents

Download PDF

Info

Publication number
JP2004525602A5
JP2004525602A5 JP2001577507A JP2001577507A JP2004525602A5 JP 2004525602 A5 JP2004525602 A5 JP 2004525602A5 JP 2001577507 A JP2001577507 A JP 2001577507A JP 2001577507 A JP2001577507 A JP 2001577507A JP 2004525602 A5 JP2004525602 A5 JP 2004525602A5
Authority
JP
Japan
Prior art keywords
nucleic acid
acid molecule
pharmaceutical composition
composition according
purified preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001577507A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004525602A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2001/012130 external-priority patent/WO2001079524A2/en
Publication of JP2004525602A publication Critical patent/JP2004525602A/ja
Publication of JP2004525602A5 publication Critical patent/JP2004525602A5/ja
Pending legal-status Critical Current

Links

JP2001577507A 2000-04-13 2001-04-13 組織特異的および病原菌特異的毒性剤、リボザイム、DNAzymeおよびアンチセンスオリゴヌクレオチドとそれらの使用方法 Pending JP2004525602A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US54844900A 2000-04-13 2000-04-13
US25181000P 2000-12-07 2000-12-07
PCT/US2001/012130 WO2001079524A2 (en) 2000-04-13 2001-04-13 Tissue-specific and pathogen-specific toxic agents, ribozymes, dnazymes and antisense oligonucleotides, and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2004525602A JP2004525602A (ja) 2004-08-26
JP2004525602A5 true JP2004525602A5 (xx) 2005-11-17

Family

ID=26941841

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001577507A Pending JP2004525602A (ja) 2000-04-13 2001-04-13 組織特異的および病原菌特異的毒性剤、リボザイム、DNAzymeおよびアンチセンスオリゴヌクレオチドとそれらの使用方法

Country Status (5)

Country Link
EP (1) EP1397489A4 (xx)
JP (1) JP2004525602A (xx)
AU (2) AU5347101A (xx)
CA (1) CA2406403A1 (xx)
WO (1) WO2001079524A2 (xx)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8183011B2 (en) * 2003-06-13 2012-05-22 University Of Medicine And Dentistry Of New Jersey RNA interferases and methods of use thereof
US20070020240A1 (en) * 2003-10-06 2007-01-25 Gangagen, Inc. Defined dose therapeutic phage
SG10201805660WA (en) 2013-12-30 2018-08-30 Curevac Ag Methods for rna analysis
US20210022324A1 (en) * 2018-03-05 2021-01-28 Dr. Reddy's Institute Of Life Sciences Embryonic zebrafish models using dnazyme mediated knockdown

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69022246T2 (de) * 1989-12-01 1996-02-29 Amoco Corp Detektion von hpv-transkripts.
GB9015845D0 (en) * 1990-07-19 1990-09-05 Emery Vincent C Diagnostic method
FR2679254B1 (fr) * 1991-07-17 1993-11-19 Clonatec Sondes oligonucleotidiques pour le typage et la detection des papillomavirus humains.
EP0642589A4 (en) * 1992-05-11 1997-05-21 Ribozyme Pharm Inc METHOD AND REAGENT TO INHIBIT VIRAL REPLICATION.
US5767259A (en) * 1994-12-27 1998-06-16 Naxcor Oligonucleotides containing base-free linking groups with photoactivatable side chains
JPH07508891A (ja) * 1993-05-06 1995-10-05 デイド、インターナショナル、インコーポレイテッド ヒト乳頭種ウイルス検出アッセイ
US6015686A (en) * 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
US5989804A (en) * 1994-07-08 1999-11-23 New England Medical Center Hospitals, Inc. E6 binding proteins
US5985662A (en) * 1995-07-13 1999-11-16 Isis Pharmaceuticals Inc. Antisense inhibition of hepatitis B virus replication
AU5298699A (en) * 1998-08-13 2000-03-06 Johnson & Johnson Research Pty. Limited Dnazymes and methods for treating hpv-related disorders
WO2002046449A2 (en) * 2000-12-07 2002-06-13 The Penn State Research Foundation Selection of catalytic nucleic acids targeted to infectious agents

Similar Documents

Publication Publication Date Title
Foldvari et al. Non-viral gene therapy: Gains and challenges of non-invasive administration methods
JP6715325B2 (ja) siRNA、siRNAを含む医薬組成物及び結合体、並びにそれらの応用
JP4709545B2 (ja) 修飾された低分子干渉rna分子および使用方法
KR102413007B1 (ko) 짧은 간섭 핵산 (siNA)을 사용한 B형 간염 바이러스 (HBV) 유전자 발현의 RNA 간섭 매개 억제
JP2020525011A (ja) 2テイル自己デリバリー型siRNAおよび関連方法
WO1999004819A1 (en) Liposomal compositions for the delivery of nucleic acid catalysts
KR900700603A (ko) 리보자임
EP2430168A1 (en) Compositions comprising cationic amphiphiles and colipids for delivering therapeutics molecules
US20040018520A1 (en) Trans-splicing enzymatic nucleic acid mediated biopharmaceutical and protein
EP3268474B1 (en) Oligonucleotides matching col7a1 exon 73 for epidermolysis bullosa therapy
JP2010532163A5 (xx)
Imai et al. Strategies of gene transfer to the kidney
CN115698288A (zh) 核酸、含有该核酸的药物组合物与siRNA缀合物及制备方法和用途
JP2004525602A5 (xx)
US7704965B2 (en) Methods and materials for treating human papillomavirus infections
WO2011130065A1 (en) RNA INTERFERENCE MEDIATED INHIBITION OF MET GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US20080317717A1 (en) Anti-hepatitis b virus ribozymal nucleic acid
TW201919654A (zh) 用於抑制α-ENaC表現之RNAi試劑及使用方法
WO2000009673A1 (en) Dnazymes and methods for treating hpv-related disorders
AU2004282998A1 (en) DNA delivery with gemini cationic surfactants
Ito et al. Liposome-mediated gene therapy in the kidney
CA2343067A1 (en) Hairpin hybridizer molecules for modulation of gene expression
EP2031059A1 (en) siDNA against hepatites C virus (HCV)
CA2797567A1 (en) Compositions and methods for reduced scarring and for treatment of fibrosis
JP2013527169A5 (xx)